Suppr超能文献

接受血管紧张素转换酶抑制剂与襻利尿剂/保钾利尿剂联合治疗的患者中可预防的猝死

Preventable sudden death in patients receiving angiotensin converting enzyme inhibitors and loop/potassium sparing diuretic combinations.

作者信息

Johnston R T, de Bono D P, Nyman C R

机构信息

Department of Cardiology, Groby Road Hospital, Leicester, U.K.

出版信息

Int J Cardiol. 1992 Feb;34(2):213-5. doi: 10.1016/0167-5273(92)90159-z.

Abstract

Angiotensin-converting-enzyme inhibitors are frequently used in conjunction with diuretics in the treatment of congestive cardiac failure. We report two cases in which use of a proprietary combination diuretic containing a loop diuretic and potassium sparing agent with an angiotensin converting enzyme inhibitor was associated with hyperkalaemic cardiac arrest. Successful resuscitation from the arrest permitted elucidation of its mechanism. We believe that this outcome has not previously been reported, and emphasise the importance of electrolyte monitoring in patients receiving angiotensin converting enzyme inhibitors particularly if prescribed in addition to fixed combination proprietary diuretics.

摘要

血管紧张素转换酶抑制剂在治疗充血性心力衰竭时经常与利尿剂联合使用。我们报告了两例使用含有襻利尿剂和保钾剂的复方专利利尿剂与血管紧张素转换酶抑制剂联合使用导致高钾血症性心脏骤停的病例。成功复苏使我们得以阐明其机制。我们认为此前尚未报道过这种结果,并强调在接受血管紧张素转换酶抑制剂治疗的患者中进行电解质监测的重要性,特别是当与复方专利利尿剂联合使用时。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验